Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Assets: 2019-2024

Historic Assets for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $260.7 million.

  • Fulcrum Therapeutics' Assets fell 22.99% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.9 million, marking a year-over-year decrease of 22.99%. This contributed to the annual value of $260.7 million for FY2024, which is 1.17% up from last year.
  • As of FY2024, Fulcrum Therapeutics' Assets stood at $260.7 million, which was up 1.17% from $257.7 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Assets ranged from a high of $260.7 million in FY2024 and a low of $129.6 million during FY2020.
  • For the 3-year period, Fulcrum Therapeutics' Assets averaged around $248.4 million, with its median value being $257.7 million (2023).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Assets soared by 81.36% in 2021, and later decreased by 3.54% in 2022.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Assets stood at $129.6 million in 2020, then spiked by 81.36% to $235.0 million in 2021, then dropped by 3.54% to $226.7 million in 2022, then rose by 13.68% to $257.7 million in 2023, then climbed by 1.17% to $260.7 million in 2024.